Grace Therapeutics Advances Dual-Source CMO Strategy

A Complete Response Letter citing CMC deficiencies, with no clinical safety or efficacy findings, has pushed Grace Therapeutics into a dual-source manufacturing posture for GTx-104, its injectable nimodipine formulation targeting aneurysmal subarachnoid hemorrhage. For QA directors and regulatory affairs leads, the case illustrates how a single CMO remediation timeline can dictate NDA resubmission strategy across an entire program.

The FDA's CRL, issued April 23, 2026, prompted a Type A Meeting whose minutes confirmed no additional clinical data were requested. Grace's current contract manufacturing organization has submitted a corrective action plan and is executing it in direct communication with the FDA; reinspection timing remains contingent on CMO readiness and FDA scheduling. In parallel, Grace initiated technology transfer to a second, U.S.-based CMO during the quarter ended September 30, 2026, beginning with analytical method transfer, a sequencing decision that reflects standard ICH Q10 lifecycle management under compressed timelines.

The dual-source approach means the NDA resubmission may be supported by either CMO or both, with timing governed by whichever site reaches readiness first. That structure distributes remediation risk but also introduces parallel validation workstreams, each carrying its own process validation and comparability obligations under 21 CFR Part 211. Required non-clinical studies identified in the CRL have also been initiated, adding a concurrent data-generation dependency to the resubmission timeline.

To fund the manufacturing and regulatory workstreams, Grace closed a $10 million private placement in August 2026 with institutional and accredited investors, extending its expected cash runway through end of calendar 2028. Research and development expenses rose to $0.9 million for the quarter ended September 30, 2026, up $0.3 million year-over-year, with the increase attributed directly to third-party costs associated with the dual-source manufacturing strategy and the CRL-identified non-clinical studies. Net loss for the quarter was $2.1 million, or $0.11 per share.

The resubmission timeline will crystallize around whichever CMO clears its readiness threshold first, a measurable checkpoint that QA and regulatory teams at similarly positioned sponsors should map against their own CMO oversight and CAPA documentation frameworks.

Source: Grace Therapeutics, Inc. via GlobeNewswire, November 12, 2026.